Picture of Biodesix logo

BDSX Biodesix News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

RCS - Accustem Sciences - AccuStem Appoints New Executive Leadership Team

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220304:nRSD7124Da&default-theme=true

RNS Number : 7124D  Accustem Sciences Limited  04 March 2022

AccuStem Sciences, Inc. Appoints New Executive Leadership Team

 

Company plans to uplist to the Nasdaq Capital Market

 

London, UK and Phoenix, AZ (March 4, 2022)- AccuStem Sciences, Inc. (OTC PINK:
ACUT), a life sciences company dedicated to improving outcomes for patients
with cancer, today announced the formation of its executive leadership team as
the first major step toward commercializing new products in the oncology
space.

 

Wendy Blosser, a commercial executive with extensive leadership experience at
diagnostic companies in the oncology sector, has been named Chief Executive
Officer and a member of the board of directors for AccuStem. Wendy most
recently served as the Chief Commercial Officer for Agendia, a leading breast
oncology company, where she led the organization to its highest sales volume
and revenue since its inception. Prior to that, Wendy served as the Chief
Commercial Officer at Biodesix where she oversaw the launch and rapid growth
of its blood-based genomic testing, GeneStrat.

 

"With the recent publication of our TransATAC analysis, I am pleased with the
StemPrintER results to date, and believe the science behind the test will be
applicable across different tumor types," said Wendy Blosser. "My vision is to
build a company that offers a multitude of products- whether it's an esoteric
diagnostic test or a novel therapeutic- that improve outcomes for cancer
patients."

 

Also joining the leadership team are Jeff Fensterer, as Chief Operations
Officer, and Joe Flanagan, as Chief Business Officer. Jeff brings an
exceptional track record in long term strategic planning that is enhanced by
his experience in a broad spectrum of roles including marketing, sales, market
access, lab operations and product development. Joe brings 25 years of sales
excellence as a strategic expert in the commercial development and successful
launch of new and on-market products. Both executives have led companies at
various stages, from early start up to Fortune 500, to consistent and rapid
growth in sales volume and revenue, most recently with Agendia.

 

With the formation of the management team, AccuStem, a spinoff from Tiziana
Life

Sciences Ltd., (NASDAQ: TLSA) will be building its corporate headquarters in
Phoenix, Arizona. The company is currently listed on the OTC PINK (ACUT) and
plans to file an application to list its common stock on the Nasdaq Capital
Market.

 

"We are pleased to have such an accomplished leadership team taking the reins
at AccuStem," said Gabriele Cerrone, Chairman. "Given the breadth of their
commercial experience in building companies such as Agendia, Biodesix and
Cytyc Corporation (now Hologic), we believe this management team has the right
skills to develop strong product and clinical research pipelines, and
ultimately successfully commercialize new technologies at AccuStem."

 

About AccuStem

 

AccuStem is a life sciences company dedicated to optimizing outcomes for all
patients with cancer across the globe. The company takes a holistic view of
its role in oncology- to empower patients and their care team with critical
answers and tools and drive innovation in healthcare.

 

 

 

Forward-Looking Statements

This press release contains "forward-looking statements" Forward-looking
statements reflect our current view about future events. When used in this
press release, the words "anticipate," "believe," "estimate," "expect,"
"future," "intend," "plan," or the negative of these terms and similar
expressions, as they relate to us or our management, identify forward-looking
statements. Such statements, include, but are not limited to, statements
contained in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook. Forward-looking
statements are based on our current expectations and assumptions regarding our
business, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the forward-looking
statements. They are neither statements of historical fact nor guarantees of
assurance of future performance. We caution you therefore against relying on
any of these forward-looking statements. Important factors that could cause
actual results to differ materially from those in the forward-looking
statements include, without limitation, our ability to raise capital to fund
continuing operations; our ability to protect our intellectual property
rights; the impact of any infringement actions or other litigation brought
against us; competition from other providers and products; our ability to
develop and commercialize products and services; changes in government
regulation; our ability to complete capital raising transactions; and other
factors relating to our industry, our operations and results of operations.
Actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of them. We
cannot guarantee future results, levels of activity, performance or
achievements. AccuStem Sciences, Inc. assumes no obligation to update any
forward-looking statements in order to reflect any event or circumstance that
may arise after the date of this release.

 

Media Contact:

Jeff Fensterer

Phone: 415-640-6010

Email: jfensterer@accustem.com (mailto:jfensterer@accustem.com)

 

Investor Contact:

Wendy Blosser

Email: investors@accustem.com (mailto:investors@accustem.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFFVLISIIF

Recent news on Biodesix

See all news